Filing Flows › Acadia Pharmaceuticals (ACAD) › Q2 2026 › vs Q1 2026
Acadia Pharmaceuticals (ACAD) Q2 2026 vs Q1 2026 (quarter over quarter)
Acadia Pharmaceuticals's revenue rose $39.9M (+15%) from $268M in Q1 2026 to $308M in Q2 2026. Operating margin 12.3% against -1.7% (+14.0 pts).
Acadia Pharmaceuticals, Q2 2026: revenue $308M (+16% year over year), operating margin 12.3%, net earnings $31.5M, operating cash flow $101M. The chart draws each line against Q1 2026, the increases inside each band.
Margins
| Q2 2026 | Q1 2026 | Change | |
|---|---|---|---|
| Operating margin | 12.3% | -1.7% | +14.0 pts |
| Net margin | 10.2% | 1.4% | +8.9 pts |
| Free cash flow margin | 31.1% | 10.7% | +20.3 pts |
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $308M | $268M | $39.9M | +15% |
| Other income, net | $8.6M | $8.6M | $40K | +0.5% |
| Operating profit | $37.8M | −$4.6M | $42.5M | — |
| Costs & expenses | $270M | $273M | −$2.6M | -0.9% |
| Pre-tax earnings | $46.5M | $4.0M | $42.5M | 12× |
| Cost of revenue | $28.3M | $24.8M | $3.5M | +14% |
| Research & development | $81.6M | $76.9M | $4.7M | +6% |
| SG&A | $160M | $171M | −$10.8M | -6% |
| Net earnings | $31.5M | $3.6M | $27.9M | +766% |
| Income tax | $15.0M | $344K | $14.6M | 44× |
| Depreciation & amortization | $3.2M | $3.0M | $164K | +5% |
| Share-based compensation | $16.9M | $14.7M | $2.2M | +15% |
| Working capital & other | $49.2M | $12.7M | $36.5M | +289% |
| Operating cash flow | $101M | $34.0M | $66.8M | +197% |
| Free cash flow (OCF − capex) | $95.7M | $28.8M | $66.9M | +233% |
| Capital expenditures | $5.1M | $5.2M | −$123K | -2% |
Questions
How much did Acadia Pharmaceuticals's revenue grow quarter over quarter in Q2 2026?
Acadia Pharmaceuticals's revenue rose $39.9M (+15%) from $268M in Q1 2026 to $308M in Q2 2026. Operating margin 12.3% against -1.7% (+14.0 pts).